@curator

2 years ago

Article

ASCO GU: Amgen's Lumakras posts encouraging results in pancreatic cancer, though not as dazzling as Mirati rival

Rating: 0.0

Likes: 1

Library: 1

ASCO GU: Amgen's Lumakras posts encouraging results in pancreatic cancer, though not as dazzling as Mirati rival

In Amgen's battle with Mirati Therapeutics to develop the best KRAS inhibitor, the biotech giant may have reached the FDA finish line first. | At the American Society of Clinical Oncology, Amgen showed in an early-stage trial of 38 patients with advanced pancreatic cancer, that Lumakras produced a 21% objective response rate, with a median progression free survival rate of four months and a median overall survival rate of 6.9 months.

Rate This Post

Rate The Educational Value

Rate The Ease of Understanding and Presentation

Interesting or Boring? Rate the Entertainment Value

ASCO GU: Amgen's Lumakras posts encouraging results in pancreatic cancer, though not as dazzling as Mirati rival

Rate This Post

Related Topics

Comments

Media:

My Account:

Boostlane:

Select a Category

Topics Trending Today

Recommended Media

Boostlane Reward System

Unlocking the Power of Knowledge
for Humanity's Progress

Quick Links

Select a Locale

Unlocking the Power of Knowledge
for Humanity's Progress

ASCO GU: Amgen's Lumakras posts encouraging results in pancreatic cancer, though not as dazzling as Mirati rival

Rate This Post

Related Topics

Comments

Media:

My Account:

Boostlane:

Select a Category

Topics Trending Today

Recommended Media

Boostlane Reward System

Unlocking the Power of Knowledge for Humanity's Progress

Quick Links

Select a Locale

Unlocking the Power of Knowledge for Humanity's Progress

Unlocking the Power of Knowledge
for Humanity's Progress

Unlocking the Power of Knowledge
for Humanity's Progress